Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | IDH2 mutant |
| Therapy | Ceralasertib + Olaparib |
| Indication/Tumor Type | Advanced Solid Tumor |
| Response Type | no benefit |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| IDH2 mutant | Advanced Solid Tumor | no benefit | Ceralasertib + Olaparib | Phase II | Actionable | In a Phase II trial, treatment with the combination of Ceralasertib (AZD6738) and Lynparza (olaparib) resulted in limited efficacy in patients with advanced solid tumors harboring mutations in IDH1 (16/24) or IDH2 (8/24), with no objective responses, clinical benefit of progression-free survival greater than 6 months in 3 patients, median progression-free survival of 2 months, and median overall survival of 7 months (J Clin Oncol 2025 43: 16_suppl, 3089; NCT03878095). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors. | Full reference... |